Medifast annual r&d spending
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Medifast R&D Spending Growth & History (MED)
Medifast's r&d spending was $4.3M for fiscal 2025.
View full Medifast company overviewMedifast annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.3M | −$300,000 | −6.52% |
| 2024 | 2024-12-31 | $4.6M | $0 | 0.00% |
| 2023 | 2023-12-31 | $4.6M | $100,000 | +2.22% |
| 2022 | 2022-12-31 | $4.5M | $100,000 | +2.27% |
| 2021 | 2021-12-31 | $4.4M | $1.6M | +57.14% |
| 2020 | 2020-12-31 | $2.8M | $100,000 | +3.70% |
| 2019 | 2019-12-31 | $2.7M | $500,000 | +22.73% |
| 2018 | 2018-12-31 | $2.2M | $700,000 | +46.67% |
| 2017 | 2017-12-31 | $1.5M | −$500,000 | −25.00% |
| 2016 | 2016-12-31 | $2.0M | $200,000 | +11.11% |
| 2015 | 2015-12-31 | $1.8M | $500,000 | +38.46% |
| 2014 | 2014-12-31 | $1.3M | — | — |
Medifast r&d spending trends
Over the last five fiscal years, Medifast's r&d spending increased from $2.8M to $4.3M, a change of $1.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Medifast source filings ↗